These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24702733)

  • 1. Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study.
    Narasimhan S; Weinstock RS
    Mayo Clin Proc; 2014 Jun; 89(6):806-16. PubMed ID: 24702733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
    ; Zeitler P; Hirst K; Pyle L; Linder B; Copeland K; Arslanian S; Cuttler L; Nathan DM; Tollefsen S; Wilfley D; Kaufman F
    N Engl J Med; 2012 Jun; 366(24):2247-56. PubMed ID: 22540912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes.
    ; Zeitler P; Epstein L; Grey M; Hirst K; Kaufman F; Tamborlane W; Wilfley D
    Pediatr Diabetes; 2007 Apr; 8(2):74-87. PubMed ID: 17448130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY.
    TODAY Study Group
    Diabetes Care; 2013 Jun; 36(6):1749-57. PubMed ID: 23704674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
    Sinha SK; Bhangoo A; Anhalt H; Maclaren N; Marshall JD; Collin GB; Naggert JK; Ten S
    J Pediatr Endocrinol Metab; 2007 Sep; 20(9):1045-52. PubMed ID: 18038714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial.
    TODAY Study Group
    Diabetes Care; 2021 Jan; 44(1):75-80. PubMed ID: 33290248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ; Bagdonas A; Rubes J; McMorn SO; Donaldson J; Biswas N; Stewart MW
    Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
    Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
    Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
    Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience.
    Marcus MD; Wilfley DE; El Ghormli L; Zeitler P; Linder B; Hirst K; Ievers-Landis CE; van Buren DJ; Walders-Abramson N;
    Pediatr Obes; 2017 Aug; 12(4):337-345. PubMed ID: 27161901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.
    Cox SL
    Drugs Today (Barc); 2004 Jul; 40(7):633-43. PubMed ID: 15510236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
    Beale S; Bagust A; Shearer AT; Martin A; Hulme L
    Pharmacoeconomics; 2006; 24 Suppl 1():21-34. PubMed ID: 16800160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.